Gland Pharma: The financial results for the period ended September 30, 2026
Gland Pharma (GLAND) filed a disclosure titled "The financial results for the period ended September 30, 2026". The company is valued at about ₹52,281 crore.
What happened
Gland Pharma (GLAND) filed a disclosure with the exchanges on 6 November 2026 at 04:33 PM titled "The financial results for the period ended September 30, 2026".
Company snapshot
Gland Pharma is a mid-cap company in the Healthcare sector, with a market value of about ₹52,281 crore.
The stock last traded at ₹3,169.3, against a 52-week range of ₹1,573.6–₹3,174 (0.1% below the high).
Before this filing the shares had moved +8.5% over the month and +24.1% over three months. Average daily turnover over the last 20 sessions was about ₹123 crore.
Promoters held 51.77% at the end of Q1 FY27, down 0.06% points from the previous quarter. Foreign institutions owned 8.74% and domestic institutions 30.44%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 1,506 | 215.5 | 13.08 |
| Q2 FY26 | 1,487 | 183.7 | 11.15 |
| Q3 FY26 | 1,695 | 261.5 | 15.87 |
| Q4 FY26 | 1,743 | 366.7 | 22.26 |
| Q1 FY27 | 1,800 | 317 | 19.23 |
What history shows
BCEIE's records show 2 previous results filings from the company since May 2026.
After those filings, the stock gained 8.4% on average the next trading day and was up 7.2% on average after five days (2 filings with price data).
Across 300 similar disclosures by other Healthcare companies, shares moved +1.3% on average the next day and +1.9% over five days; 57% of them rose the next day.
Market-wide, 10,840 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 42% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 10 Aug 2026 | Board Meeting Outcome for Unaudited Financial Results For The… | +8.4% | +7.2% |
| 10 Aug 2026 | Unaudited Financial Results For The Quarter Ended June 30, 2026 | +8.4% | +7.2% |
What to watch
- Management commentary, margins and order book or guidance in the investor presentation.
- 6 November 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
- U.S. FDA issues four observations to Gland Pharma formulation facility near Hyderabad
- Gland Pharma Limited (GLAND.NS) Seasonal returns chart - Yahoo Finance
- Gland Pharma Appoints Ajay Sahni as CEO of Singapore-Based International Subsidiary
- Gland Pharma names Ajay Sahni CEO of Singapore subsidiary
- Gland Pharma Wins USFDA Nod for Generic Depo-Medrol Injection
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.